Search results
Results from the WOW.Com Content Network
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
Bravecto 1-Month was approved by the FDA in November 2024 for the addition of the indication for the treatment and control of Haemaphysalis longicornis (Asian longhorned tick) infestations for one month in dogs and puppies eigjht weeks of age and older, and weighing 4.4 pounds (2.0 kg) or greater.
Jazz Pharmaceuticals (JAZZ) shares slumped more than 5% in premarket trading Monday after the Palo Alto, Calif.-based company announced that, as expected, the Food and Drug Administration had ...
The drugs, while used to treat diabetes, show promise in reducing the risk of age-related diseases and kidney disease, by reducing oxidative stress and inflammation, and improving heart health and ...
Before a drug can be prescribed, it must undergo the FDA's approval process. While a drug can feasibly be used off-label (for non-approved indications), it still is required to be approved for a specific disease or medical condition. [2] Drug companies seeking to sell a drug in the United States must first test it.
The FDA approval for Zenrelia carries a boxed warning stating that dogs should not be vaccinated at least 28 days before and after treatment with the drug, due to the risk of fatal vaccine-induced ...
The clinical trial was stopped early because the drug showed significant benefit; it reduced mortality by 43%, reduced hospitalizations by 39%, and improved quality of life markers in African-American patients with CHF. [9] On the basis of A-HeFT, the FDA approved BiDil in June 2005.